Loading...

We've got a brand new version of Simply Wall St! Try it out

Unibios Holdings

ATSE:BIOSK
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BIOSK
ATSE
€1M
Market Cap
  1. Home
  2. GR
  3. Capital Goods
Company description

Unibios Holdings S.A., through its subsidiaries, develops and installs water treatment systems in Europe. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
BIOSK Share Price and Events
7 Day Returns
-5.6%
ATSE:BIOSK
2.9%
Europe Machinery
-1.6%
GR Market
1 Year Returns
14.7%
ATSE:BIOSK
9.4%
Europe Machinery
30.7%
GR Market
BIOSK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Unibios Holdings (BIOSK) -5.6% -0.8% 1.1% 14.7% -51.4% -59.8%
Europe Machinery 2.9% 9.2% 14.4% 9.4% 21.2% 40.3%
GR Market -1.6% 1.8% 6.2% 30.7% 49.3% -75.1%
1 Year Return vs Industry and Market
  • BIOSK outperformed the Machinery industry which returned 9.4% over the past year.
  • BIOSK underperformed the Market in Greece which returned 30.7% over the past year.
Price Volatility
BIOSK
Industry
5yr Volatility vs Market

Value

 Is Unibios Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Unibios Holdings. This is due to cash flow or dividend data being unavailable. The share price is €0.374.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Unibios Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Unibios Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ATSE:BIOSK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in EUR €-0.08
ATSE:BIOSK Share Price ** ATSE (2019-11-11) in EUR €0.37
Europe Machinery Industry PE Ratio Median Figure of 194 Publicly-Listed Machinery Companies 16.44x
Greece Market PE Ratio Median Figure of 92 Publicly-Listed Companies 16.93x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Unibios Holdings.

ATSE:BIOSK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ATSE:BIOSK Share Price ÷ EPS (both in EUR)

= 0.37 ÷ -0.08

-4.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unibios Holdings is loss making, we can't compare its value to the Europe Machinery industry average.
  • Unibios Holdings is loss making, we can't compare the value of its earnings to the Greece market.
Price based on expected Growth
Does Unibios Holdings's expected growth come at a high price?
Raw Data
ATSE:BIOSK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.7x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Machinery Industry PEG Ratio Median Figure of 127 Publicly-Listed Machinery Companies 1.19x
Greece Market PEG Ratio Median Figure of 26 Publicly-Listed Companies 1.04x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Unibios Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Unibios Holdings's assets?
Raw Data
ATSE:BIOSK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in EUR €3.16
ATSE:BIOSK Share Price * ATSE (2019-11-11) in EUR €0.37
Europe Machinery Industry PB Ratio Median Figure of 272 Publicly-Listed Machinery Companies 1.58x
Greece Market PB Ratio Median Figure of 134 Publicly-Listed Companies 0.9x
ATSE:BIOSK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ATSE:BIOSK Share Price ÷ Book Value per Share (both in EUR)

= 0.37 ÷ 3.16

0.12x

* Primary Listing of Unibios Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unibios Holdings is good value based on assets compared to the Europe Machinery industry average.
X
Value checks
We assess Unibios Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Machinery industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Machinery industry average (and greater than 0)? (1 check)
  5. Unibios Holdings has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Unibios Holdings expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Unibios Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.7%
Expected Machinery industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Unibios Holdings expected to grow at an attractive rate?
  • Unable to compare Unibios Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Unibios Holdings's earnings growth to the Greece market average as no estimate data is available.
  • Unable to compare Unibios Holdings's revenue growth to the Greece market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ATSE:BIOSK Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Machinery Industry Earnings Growth Rate Market Cap Weighted Average 9.7%
Europe Machinery Industry Revenue Growth Rate Market Cap Weighted Average 3.2%
Greece Market Earnings Growth Rate Market Cap Weighted Average 17.9%
Greece Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ATSE:BIOSK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ATSE:BIOSK Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-06-30 7 0 0
2019-03-31 8 -1 0
2018-12-31 8 -1 0
2018-09-30 8 -1 0
2018-06-30 7 -1 0
2018-03-31 6 0 0
2017-12-31 5 0 0
2017-09-30 5 0 -1
2017-06-30 5 0 -2
2017-03-31 5 0 -2
2016-12-31 5 0 -2
2016-09-30 6 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Unibios Holdings is high growth as no earnings estimate data is available.
  • Unable to determine if Unibios Holdings is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ATSE:BIOSK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Unibios Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ATSE:BIOSK Past Financials Data
Date (Data in EUR Millions) EPS *
2019-06-30 -0.08
2019-03-31 -0.09
2018-12-31 -0.11
2018-09-30 -0.05
2018-06-30 0.01
2018-03-31 -0.04
2017-12-31 -0.08
2017-09-30 -0.33
2017-06-30 -0.58
2017-03-31 -0.56
2016-12-31 -0.54
2016-09-30 -0.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Unibios Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Unibios Holdings's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Capital Goods companies here
  2. Unibios Holdings's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Unibios Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Unibios Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Unibios Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Unibios Holdings's growth in the last year to its industry (Machinery).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Unibios Holdings does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Unibios Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Unibios Holdings's 1-year growth to the Europe Machinery industry average as it is not currently profitable.
Earnings and Revenue History
Unibios Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Unibios Holdings Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ATSE:BIOSK Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 7.40 -0.25 2.55
2019-03-31 7.69 -0.29 2.72
2018-12-31 7.98 -0.33 2.89
2018-09-30 7.69 -0.16 2.90
2018-06-30 7.40 0.02 2.91
2018-03-31 6.39 -0.11 2.71
2017-12-31 5.38 -0.24 2.52
2017-09-30 5.10 -1.02 2.55
2017-06-30 4.82 -1.81 2.57
2017-03-31 4.68 -1.76 2.61
2016-12-31 4.53 -1.70 2.64
2016-09-30 6.13 -0.47 2.46
2016-06-30 6.19 0.18 2.29
2016-03-31 6.87 -0.20 2.55
2015-12-31 6.44 -0.43 2.54
2015-09-30 6.72 -0.94 3.13
2015-06-30 7.52 -0.67 3.11
2015-03-31 7.89 -0.23 3.01
2014-12-31 8.22 -0.15 3.11
2014-09-30 8.62 -0.34 2.99
2014-06-30 8.80 -0.34 3.28
2014-03-31 9.30 -0.21 3.32
2013-12-31 9.47 -0.16 3.32
2013-09-30 7.83 -0.64 3.20
2013-06-30 8.00 -1.28 3.42
2013-03-31 7.02 -1.89 3.55
2012-12-31 7.30 -2.15 3.81

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Unibios Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Unibios Holdings used its assets less efficiently than the Europe Machinery industry average last year based on Return on Assets.
  • It is difficult to establish if Unibios Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Unibios Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Machinery industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Unibios Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Unibios Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Unibios Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Unibios Holdings's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Unibios Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Unibios Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Unibios Holdings Company Filings, last reported 4 months ago.

ATSE:BIOSK Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 9.97 2.84 0.10
2019-03-31 9.97 2.84 0.10
2018-12-31 8.28 4.17 0.07
2018-09-30 8.28 4.17 0.07
2018-06-30 8.60 5.71 0.34
2018-03-31 8.60 5.71 0.34
2017-12-31 8.66 3.06 0.11
2017-09-30 8.66 3.06 0.11
2017-06-30 8.73 1.42 0.38
2017-03-31 8.73 1.42 0.38
2016-12-31 9.04 1.46 0.32
2016-09-30 9.04 1.46 0.32
2016-06-30 10.87 1.51 0.24
2016-03-31 10.87 1.51 0.24
2015-12-31 11.08 1.59 0.75
2015-09-30 10.71 1.95 0.56
2015-06-30 10.81 2.00 0.97
2015-03-31 11.27 1.65 1.36
2014-12-31 11.58 1.60 0.12
2014-09-30 11.63 1.70 0.39
2014-06-30 11.49 2.11 0.27
2014-03-31 11.52 1.66 0.34
2013-12-31 11.76 1.18 0.32
2013-09-30 11.81 1.75 0.46
2013-06-30 11.60 2.14 0.21
2013-03-31 11.48 2.30 0.30
2012-12-31 11.36 2.29 0.44
  • Unibios Holdings's level of debt (28.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (13.9% vs 28.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Unibios Holdings has less than a year of cash runway based on current free cash flow.
  • Unibios Holdings has less than a year of cash runway if free cash flow continues to grow at historical rates of 27.4% each year.
X
Financial health checks
We assess Unibios Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Unibios Holdings has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Unibios Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Unibios Holdings dividends.
If you bought €2,000 of Unibios Holdings shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Unibios Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Unibios Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ATSE:BIOSK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Machinery Industry Average Dividend Yield Market Cap Weighted Average of 153 Stocks 2.8%
Greece Market Average Dividend Yield Market Cap Weighted Average of 50 Stocks 4%
Greece Minimum Threshold Dividend Yield 10th Percentile 1.2%
Greece Bottom 25% Dividend Yield 25th Percentile 1.9%
Greece Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Unibios Holdings has not reported any payouts.
  • Unable to verify if Unibios Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Unibios Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Unibios Holdings has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Unibios Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Unibios Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Unibios Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Unibios Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Nik Mavrikios
CEO Bio

Mr. Orfeas Nikolau Mavrikios, also known as Nik, serves as Chief Executive Officer, Vice Chairman and Managing Director at Unibios Holdings S.A. He holds Bachelor's degree in Economics at Hamilton College from 1978 to 1982 and M.B.A in Finance, Marketing, Operations Management at Northwestern University from 1982 to 1984.

CEO Compensation
  • Insufficient data for Nik to compare compensation growth.
  • Insufficient data for Nik to establish whether their remuneration is reasonable compared to companies of similar size in Greece.
Management Team

Antony Svoronos

TITLE
Chairman
AGE
58

Nik Mavrikios

TITLE
Vice-Chairman

George Bekos

TITLE
Group CFO & Executive Director

Anastasios Theodorakopoulos

TITLE
Executive Director

Ilias Giannakopoulos

TITLE
Executive Director
Board of Directors

Antony Svoronos

TITLE
Chairman
AGE
58

Nik Mavrikios

TITLE
Vice-Chairman

George Bekos

TITLE
Group CFO & Executive Director

Anastasios Theodorakopoulos

TITLE
Executive Director

Ilias Giannakopoulos

TITLE
Executive Director

Ioannis Methodios

TITLE
Independent Non-Executive Director

Nikolaos Travlos

TITLE
Independent Non-Executive Director

Rigas-Alexandros Karavias

TITLE
Independent Non-Executive Director

Alexandros Kalogirou

TITLE
Independent Non-Executive Director

Georgios Papathanasiou

TITLE
Independent Non Executive Director
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Unibios Holdings individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Sep 19 Buy Antonios Svoronos Individual 18. Sep 19 18. Sep 19 2,821,852 €0.30 €846,555
02. Aug 19 Sell Antonios Svoronos Individual 02. Aug 19 02. Aug 19 -154,500 €0.39 €-24,150
02. Aug 19 Buy Antonios Svoronos Individual 02. Aug 19 02. Aug 19 173,669 €0.39 €26,181
30. Jul 19 Sell Antonios Svoronos Individual 30. Jul 19 30. Jul 19 -40,000 €0.15 €-6,000
30. Jan 19 Sell Antonios Svoronos Individual 30. Jan 19 30. Jan 19 -31,023 €0.33 €-10,238
X
Management checks
We assess Unibios Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Unibios Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Does Unibios Holdings S.A. (ATH:BIOSK) Affect Your Portfolio Volatility?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … This is reasonably close to the market beta of 1, so the stock has in the past displayed similar levels of volatility to the overall market. … Therefore, it's a bit surprising to see that this stock has a beta value so close to the overall market.

Simply Wall St -

What Does Unibios Holdings S.A.'s (ATH:BIOSK) Balance Sheet Tell Us About It?

BIOSK has built up its total debt levels in the last twelve months, from €7.7m to €8.8m – this includes long-term debt. … At the current liabilities level of €7.8m, it seems that the business may not have an easy time meeting these commitments with a current assets level of €6.3m, leading to a current ratio of 0.81x. … The current ratio is the number you get when you divide current assets by current liabilities.

Simply Wall St -

Does The Unibios Holdings S.A. (ATH:BIOSK) Share Price Tend To Follow The Market?

(ATH:BIOSK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … The first thing to understand about beta is that the beta of the overall market is one.

Simply Wall St -

Some Unibios Holdings (ATH:BIOSK) Shareholders Have Taken A Painful 84% Share Price Drop

While Unibios Holdings made a small profit, in the last year, we think that the market is probably more focussed on the top line growth at the moment. … Generally speaking, companies that are not judged on their (small) profits should be growing revenue quickly. … Over half a decade Unibios Holdings reduced its trailing twelve month revenue by 11% for each year.

Simply Wall St -

Should You Worry About Unibios Holdings S.A.’s (ATH:BIOSK) ROCE?

To be precise, we'll consider its Return On Capital Employed (ROCE), as that will inform our view of the quality of the business. … What is Return On Capital Employed (ROCE)? … The formula for calculating the return on capital employed is:

Simply Wall St -

What You Must Know About Unibios Holdings S.A.'s (ATH:BIOSK) Financial Strength

Investors are always looking for growth in small-cap stocks like Unibios Holdings S.A. … However, an important fact which most ignore is: how financially healthy is the business? … I believe these basic checks tell most of the story you need to know.

Simply Wall St -

How Much Of Unibios Holdings SA (ATH:BIOSK) Do Insiders Own?

The big shareholder groups in Unibios Holdings SA (ATH:BIOSK) have power over the company. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Unibios Holdings is not a large company by global standards.

Simply Wall St -

What Investors Should Know About Unibios Holdings SA's (ATH:BIOSK) Financial Strength

Investors are always looking for growth in small-cap stocks like Unibios Holdings SA (ATH:BIOSK), with a market cap of €1.58m. … However, an important fact which most ignore is: how financially healthy is the business? … the current state of its operations and pathway to profitability.

Simply Wall St -

Why Unibios Holdings SA's (ATH:BIOSK) Investor Composition Impacts Your Returns

In this article, I will take a quick look at Unibios Holdings SA’s (ATH:BIOSK) recent ownership structure – an unconventional investing subject, but an important one. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine BIOSK's ownership structure in more detail.

Simply Wall St -

Who Are The Top Investors In Unibios Holdings SA. (ATH:BIOSK)?

View our latest analysis for Unibios Holdings ATSE:BIOSK Ownership_summary May 10th 18 Insider Ownership Another important group of shareholders are company insiders. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors. … Private Company Ownership Potential investors in BIOSK should also look at another important group of investors: private companies, with a stake of 1.04%, who are primarily invested because of strategic and capital gain interests.

Simply Wall St -

Company Info

Description

Unibios Holdings S.A., through its subsidiaries, develops and installs water treatment systems in Europe. It also distributes products and systems for the heating and air conditioning of buildings. Unibios Holdings S.A. also exports its products to Africa and the Middle East. The company was formerly known as Biossol SA and changed its name to Unibios Holdings S.A. in July 2008. Unibios Holdings S.A. was founded in 1940 and is based in Ano Liosia, Greece.

Details
Name: Unibios Holdings S.A.
BIOSK
Exchange: ATSE
Founded: 1940
€1,161,248
3,104,942
Website: http://www.unibios.gr
Address: Unibios Holdings S.A.
1st and 18th Street,
Ano Liosia,
133 41,
Greece
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ATSE BIOSK Ordinary Shares The Athens Stock Exchange GR EUR 28. Jul 1993
Number of employees
Current staff
Staff numbers
0
Unibios Holdings employees.
Industry
Industrial Machinery
Capital Goods
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/11 20:44
End of day share price update: 2019/11/11 00:00
Last earnings filing: 2019/09/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.